Meeting
2014 ASCO Annual Meeting
SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).
Authors
Saad Zafar Usmani
Carolinas Healthcare System, Charlotte, NC
Saad Zafar Usmani , Antje Hoering , Rachel Sexton , Sikander Ailawadhi , Jatin J. Shah , Sandi Fredette , Brian G. Durie , Jeffrey A. Zonder , Madhav V. Dhodapkar , S. Vincent Rajkumar , Anuj Kumar Mahindra , Todd M. Zimmerman , Paul G. Richardson , Robert Z. Orlowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01668719
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8624)
DOI
10.1200/jco.2014.32.15_suppl.tps8624
Abstract #
TPS8624
Poster Bd #
304B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).
First Author: Saad Zafar Usmani
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2013 ASCO Annual Meeting
A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
First Author: James D. Hilger
Poster
2024 ASCO Annual Meeting
Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.
First Author: Jeries Kort